INDIANAPOLIS and BOSTON, Oct. 18, 2022 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Akouos, Inc. (NASDAQ: AKUS) today announced a definitive agreement for Lilly to acquire Akouos, a precision genetic medicine company that is developing a portfolio of first-in-class adeno-associated viral gene therapies for the treatment of inner ear conditions, including sensorineural hearing loss. “We are honored to work with the talented team at Akouos who are breaking new ground in the science of treating hearing loss,” said Andrew C. Adams, Ph.D., senior vice president of genetic medicine and co-director of the Institute for Genetic Medicine, Lilly.

Oculis is focused on becoming a leading global ophthalmic biopharmaceutical company with product candidates to address areas of significant medical needs, including diabetic macular edema (DME), dry eye disease (DED), and neuro-retina indications such as glaucoma, affecting growing patient populations

Study met both co-primary endpoints and all secondary endpoints. At week eight, 67.3% of individuals treated with roflumilast foam achieved Scalp-Investigator Global Assessment (S-IGA) Success compared to 28.1% of individuals treated with vehicle
At week eight, 46.5% of individuals treated with roflumilast foam achieved Body-Investigator Global Assessment (B-IGA) Success compared to 20.8% of individuals treated with vehicle
Once-daily roflumilast foam demonstrated a favorable safety and tolerability profile

NEW HAVEN, Conn.–(BUSINESS WIRE)–Rallybio Corporation (Nasdaq: RLYB) today announced positive preliminary results from its ongoing Phase 1b proof-of-concept study of RLYB212, an anti-HPA-1a monoclonal antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). These data demonstrate that one week after a single subcutaneous dose, RLYB212 was able to eliminate transfused HPA-1a positive platelets rapidly compared to placebo in a challenge model of a catastrophic fetal maternal hemorrhage. Additional pharmacokinetic data suggests the opportunity for less frequent dosing.

Palo Alto, Calif., Sept. 28, 2022 – Evommune, Inc., a clinical-stage biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases, today announced enrollment of the first patient in a Phase 2a proof-of-concept clinical trial evaluating EVO101, a novel small molecule inhibitor of interleukin 1 receptor-associated kinase 4 (IRAK4), in patients with atopic dermatitis (AD). The Phase 2a trial is a randomized, double-blind, parallel group, vehicle-controlled study which will assess the safety, tolerability and preliminary efficacy of EVO101 topical cream, 0.1% BID, in 118 adults with mild to moderate AD in clinical sites
across the United States.

Plexium, Inc. (Plexium), a leading next-generation targeted protein degradation (TPD) company, today announced the appointment of Daniel Sipes as Senior Vice President, Head of Technology. Mr. Sipes brings over two decades of experience in developing and implementing new technologies for drug discovery to Plexium, with a focus on next-generation high throughput screening and novel assay development.

Karuna Therapeutics (KRTX) topped expectations Monday in a study of its schizophrenia treatment, and the biotech stock soared to a record high.On the stock market today, biotech stock Karuna catapulted 71.8% to 241.19. The company tested its drug in patients with schizophrenia for five weeks. At the end of the test, patients who received the drug showed a 9.6-point reduction on a scale of symptoms compared to the placebo recipients. The scale measures 30 items related to psychopathic behavior.

First and only topical PDE4 inhibitor approved for the treatment of plaque psoriasis, including intertriginous psoriasis
Approved for once-daily treatment in mild, moderate, and severe plaque psoriasis with no limitations on duration of use
Established efficacy – provides rapid clearance of plaques and reduction of itch in all affected areas of the body
Safe and very well-tolerated, steroid-free cream with minimal application site reactions
Commercial product expected to be available by mid-August
Management will host conference call on Monday, August 1 at 8:30 a.m. EDT

Sanofi has out-licensed its KY1066 antibody to New Haven, CT-based Rallybio who has redubbed it RLYB331. The deal saw Rallybio make an upfront cash payment of $3 million to Sanofi in addition to promising development and commercial milestones and mid to high single-digit royalties on net sales.

San Diego, California, [April 28, 2022] – Plexium, Inc. (Plexium) and AbbVie (NYSE: ABBV) have entered into an exclusive strategic collaboration to develop

Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical

Marks key milestone as Evommune’s first clinical program which should allow EVO101 to rapidly advance into Phase 2a

SAN DIEGO, Feb. 23, 2022 /PRNewswire/ — Plexium, Inc. (Plexium),

In the bustling biotech space, a couple years can feel like an eternity — but for an Atlas Venture-backed neurology player with a novel spin on R&D, a few quiet years aren’t the worst thing in the world.

As pharma continues to seek new breakthroughs across drug modalities, few areas have garnered more interest than protein degradation. And Amgen is taking a flyer out on a small biotech that thinks its broad approach to degrader R&D could spell a fruitful relationship with the drug giant.

Boston, Mass., Nov 29, 2021 — HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of first-in-class allosteric therapies targeting regulatory sites on proteins referred to as “natural hotspots,” today announced the close of its oversubscribed $100 million Series C financing, bringing its total funding to $190 million.

HotSpot Therapeutics, the allostery-focused biotech that works on what it calls “natural hotspots” — hence the name — is getting a bit hotter in its valuation from investors. And to that end they’ve raised $100 million.

The four-year-old AI computational biotech started by two former Nimbus execs announced this morning that it closed its Series C round right at the line of a 9-figure investment, courtesy of some big investors.

SAN DIEGO–(BUSINESS WIRE)–Engrail Therapeutics™ (Engrail) (the Company), a neuroscience company focused on the acquisition, development and commercialization of patient-centric therapies and The Texas A&M University System (TAMUS),

Thursday, too, saw Exscientia raise more than just the IPO. In conjunction with the pricing, the Oxford, UK-based biotech got another $160 million in private placements from SoftBank and the Bill and Melinda Gates Foundation. With the debut, details about the big IPO winners are coming into focus. The biggest shareholder is now SoftBank, which will get a 16.3% stake after the offering. CEO Andrew Hopkins is second on the list with 15.8% of shares.

Funding to Advance Pipeline of Engineered TIL Therapies for Solid Tumors into Clinical Studies
Existing investors Atlas Venture, Vertex Ventures HC, Amgen Ventures, and Bristol Myers Squibb participated in the financing.Also participating in the round is Vertex Pharmaceuticals, with whom Obsidian recently executed a collaboration to discover novel therapies that regulate gene editing.

The financing enables Evommune to continue the research and development of transformative therapies through both industry and academic collaborations to treat patients with immune-mediated and chronic inflammatory diseases.
This financing will allow us to advance all four of the programs in our pipeline into the clinic.”

A couple of years ago, Amgen joined Big Pharma’s mass exodus from neuroscience, as execs either abandoned or trimmed back their programs in the field.

Now, a small Cambridge, MA-based biotech is sprinting toward the clinic with two of Amgen’s old TREM2 assets, and investors are putting down $90 million ahead of what they believe could be neuroscience’s big comeback.

This exciting collaboration will provide a unique opportunity to combine Genmab’s innovative bispecific antibody technologies with Bolt’s powerful, advanced ISAC technology to develop targeted antibody products with the potential to transform cancer treatment

Second clinical molecule from Exscientia collaboration with Sumitomo Dainippon Pharma to begin Phase 1 trials in United States.

While hearing health issues have historically been under-emphasized, it’s estimated that 360 million people suffer from some form of hearing loss (over 5% of the global population) worldwide…

BOSTON, Feb. 04, 2021 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics….

SAN DIEGO–(BUSINESS WIRE)–Engrail Therapeutics™ (Engrail) today announced that it has acquired NeuroCycle Therapeutics, a company focused on sub-type selective GABA-A modulation…

WESTLAKE VILLAGE, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a medical dermatology company developing innovative…

SAN DIEGO, Jan. 21, 2021 /PRNewswire/ — Plexium, Inc., (Plexium), a biotech company focused on discovering and developing protein degrading…

WESTLAKE VILLAGE, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing…

WESTLAKE VILLAGE, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a medical dermatology company developing innovative…

LOS ALTOS, Calif., Jan. 7, 2021 /PRNewswire/ — Evommune, Inc., a private R&D company and innovation engine in chronic inflammation…

Seven weeks after Eli Lilly and Co. bought skin drug company Dermira Inc. for $1.1 billion last year, just as the Covid-19 pandemic…

About a year after Eli Lilly absorbed Dermira in a $1 billion buyout, the dermatology company’s co-founders are licensing back three inflammatory disease…

FOSTER CITY, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) — Vaxcyte, Inc., a next-generation vaccine company seeking to improve global health…

Los Altos, Calif., Jan. 5, 2021 – Evommune, Inc., a private R&D company and innovation engine in chronic inflammation, today announced…

Los Altos, California, USA and Fujisawa, Kanagawa, Japan–Dec. 10, 2020 –Evommune, Inc., aprivate R&D company andinnovation engine…

SAN FRANCISCO, CA, November 30, 2020 – MapLight Therapeutics today announced a $8.1 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF)…

SAN FRANCISCO, November 23, 2020 – MapLight Therapeutics today announced it has completed dosing of healthy volunteers across five cohorts in a Phase 1…

LOS ALTOS, Calif., Nov. 18, 2020 /PRNewswire/ — Evommune, Inc., an innovation engine in chronic inflammation, announced the successful completion of a $12.5 million…

Los Altos, California –Nov. 18, 2020 –Evommune, Inc.,an innovation engine inchronic inflammation,announced the successful completion…

BOSTON–(BUSINESS WIRE)–Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company

BOSTON, July 23, 2020 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc.

BOSTON, June 30, 2020 (GLOBE NEWSWIRE) — Akouos, Inc. (“Akouos”)

Vaxcyte Inc. PCVX, +59.37% priced its initial public offering late

WESTLAKE VILLAGE, Calif., Feb. 04, 2020 (GLOBE NEWSWIRE) — Arcutis

HAMILTON, ON and BOSTON, June 25, 2020 /PRNewswire/ — Fusion

BOSTON, July 30, 2020 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc.

2020-03-11 – Arctic Vision to Lead Expansion of Novel Approach

Shanghai, July 13, 2020 /PRNewswire/ — Arctic Vision, a clinical-stage

SAN DIEGO–(BUSINESS WIRE)–Engrail Therapeutics™ (Engrail) (the Company), a neuroscience company focused on the acquisition, development and commercialization of patient-centric therapies…

Shanghai, China, July 14 – Arctic Vision, a clinical-stage biotechnology company incubated by Nan Fung Life Sciences and Pivotal BioVenture Partners China in 2019…

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) announces 19 new grant awards totaling more than $16.5 million…

SAN DIEGO–(BUSINESS WIRE)–Engrail Therapeutics™ (Engrail) (the Company) today announced the close of a $32 million Series A financing round…

Vijai Mohan, CEO of STS, on the Impact of COVID-19

In the spring of 2014, a small Michigan biotech closed a $6.5 million deal to buy several cell therapies from the French drug giant Sanofi. They included a technology to treat weekend…

Almost 48 million Americans suffer from some sort of hearing loss—and while many could benefit from a hearing aid, some are reluctant to wear them for aesthetic reasons…

Eargo, the health tech company that’s destigmatizing hearing loss through consumer-driven innovation, was awarded Best Companies for Perks & Benefits for this quarter’s Comparably Award…

Eargo, the health tech company that’s destigmatizing hearing loss through consumer-driven innovation, was awarded Best Technological Innovation – Consumer Devices…

Eargo, the health tech company that’s destigmatizing hearing loss through consumer-driven innovation, was awarded Gold for its Eargo Max hearing aid in the Medical & Health…

An adult hearing device, a baby bassinet, a home speaker, a security system and an entertainment headset are among the 2018 International Design Excellence Awards’ top winners with significant plastics content…

On Sept. 19, the Industrial Designers Society of America (IDSA) announced the Gold, Silver and Bronze winners of the International Design Excellence Awards (IDEA)…

Eargo, the health tech company that’s destigmatizing hearing loss through consumer-driven innovation, was named an honoree by Fast Company in its annual Innovation by Design Awards for 2018…

Fast Company’s 2018 Annual Innovation By Design Awards | Health

Eargo is a Class I, FDA-regulated hearing device designed for adults experiencing mild to moderate hearing loss. Invented by an ENT surgeon with more than 30 years’ experience…

Boston, US and Shanghai China — (Business Wire) —June 7, 2017— Oncologie, an innovative biopharmaceutical company, announced today that it is launching…

Boston, US and Shanghai China — (Business Wire) —June 7,

PreSeries predictive algorithms crawl the web hungry for startup information. So far, almost 400k companies have been ruthlessly processed, scored, and ranked…

Shanghai, China— (BUSINESS WIRE)—May 24, 2018— Pivotal bioVenture Partners China (Pivotal China), a member of Nan Fung Life Sciences (NLFS) announced…

Eargo Max delivers advanced sound quality for more gain and volume +(5dB). And with our patent-pending Flexi Domes, you get even greater volume and fuller sound…

Introducing the IAB 250-Powered by Dun & Bradstreet. DirectBrands Worth Watching

CES 2018 was, as usual, filled with futuristic and fascinating new technologies and devices. But much of this new gear is likely never make it to market, or is more provocative than practical…

CES the Consumer Electronics Show is a massive whirlwind of amazing gadgets, prototypes, and re-hashes from the past…

LAS VEGAS — Unless you’ve been living under a rock, or are perhaps a company executive or a member of Congress with a gold-plated…

Every year at the Consumer Electronics Show in Las Vegas, we get a glimpse of the best technology of today and tomorrow…

HOLY GRAIL OF HEARING AID TECHNOLOGY BY ‘EARGO’By Eric Blair• Jan11, 2018Nearly 48 million people in America have some level of hearing loss…

The CES crowd seems to be dwindling every year as more tech companies wait until events like Mobile World Congress or their own developer shows to announce new products…

Hearing aids aren’t necessarily the thing you think of when you’re listing the most innovative new products of the past few years….

Tonight I had the pleasure of meeting Raphael, Founder and Chief Strategy Officer of Eargo. This company has designed the world’s smallest hearing aids that almost look like fishing lures…

Mountain View, Calif. – Jan. 09, 2018 /PRNewswire/– Eargo, the award-winning, direct-to-consumer hearing technology company, today announced the launch of Eargo Max, their best hearing aid yet.

SAN FRANCISCO (KGO) — Some potentially life-saving innovations are on display this week at the JP Morgan Healthcare Conference in San Francisco…

Vericel on Westwood One

We find ourselves spending less time in the pub these days. Not because we don’t like to drink anymore-on the contrary,we have more reasons than ever….

Mountain View, Calif. – Oct. 19, 2017 – Eargo (www.eargo.com), the innovative, direct-to-consumer hearing technology company renowned for the world’s smallest, most comfortable, and rechargeable hearing aid…

Generic hearing aids available on the market are for the most part, not very aesthetically pleasing. They are often large and clunky, making their presence well-known to their wearer and those around them…

Vericel on Bloomberg Business of Sport Report

Shares in Cambridge-based Vericel Corp (NSDQ:VCEL) surged last year after the FDA approved its bioresorbable scaffold for cartilage repair…

Shares of Cambridge-based Vericel surged late Tuesday after the FDA approved a treatment for knee cartilage repair that involves harvesting a patient’s own cells…

It wasn’t too long ago that we kicked off our mission in earnest to provide a new solution to help empower those with hearing loss. We’re here to make hearing easy; there’s never been more of a need…

Just like our customers, most of us who work at Eargo are unique in almost every way imaginable. Some of us are night owls, some of us early risers. Some of us listen to the Beatles, others went to their concerts…